Skip to content
value.today

Oruka Therapeutics, Inc.

ORKA
$6.5 Bmarket cap on Oct 28, 2026+26975.3% since Jan 2024
Compare
World rank
#2,970
Revenue
—
For year ending December-2025
Net income
$-105 M
SEC filing
Employees
68
As of December 31, 2025
value.today research

Oruka Therapeutics, Inc. in brief

Oruka Therapeutics, Inc. is a listed company in the Biotechnology industry, based in the USA. Its market value was $6.5 B on 28 October 2026, which makes it the 2,970th largest listed company in the world and the 897th largest in the USA on this site. It employs about 68 people. Its shares trade under the symbol ORKA (Nasdaq).

Written from the figures on this page, so it changes when they do. Dates and sources are under Sources and freshness.

About Oruka Therapeutics, Inc.

On August 29, 2024, we completed our acquisition of Oruka Therapeutics, Inc. pursuant to an Agreement and Plan of Merger and Reorganization, dated as of April 3, 2024. Following the transactions contemplated by the Merger Agreement, Pre-Merger Oruka merged with and into Atlas Merger Sub Corp., a wholly owned subsidiary of ARCA biopharma, Inc. and following that, Pre-Merger Oruka then merged with and into Atlas Merger Sub II, LLC, with Second Merger Sub being the surviving entity. Second Merger Sub changed its corporate name to “Oruka Therapeutics Operating Company, LLC”. Pre-Merger Oruka was a pre-clinical stage biotechnology company that was incorporated on February 6, 2024 under the direction of Peter Harwin, a Founding Partner at Fairmount Funds Management LLC, for the purposes of holding rights to certain intellectual property being developed by Paragon Therapeutics, Inc.. On August 29, 2024, we changed our name from “ARCA biopharma, Inc.” to “Oruka Therapeutics, Inc.” and our Nasdaq ticker symbol from “ABIO” to “ORKA”.

Oruka Therapeutics, Inc. timeline

4 events, 1997–2024
  1. 1997
  2. •
    · approximate
    First filing with the US SEC
    The company's first electronic filing in SEC EDGAR.
  3. 2003
  4. ✎
    Renamed Nuvelo Inc
    Formerly Hyseq Inc.
  5. 2009
  6. ✎
    Renamed ARCA biopharma, Inc.
    Formerly Nuvelo Inc.
  7. 2024
  8. ✎
    Renamed Oruka Therapeutics, Inc.
    Formerly ARCA biopharma, Inc..

Events of Oruka Therapeutics, Inc. from SEC EDGAR. Dates marked approximate come from statements without a cited source. Spotted a mistake? Use the correction form below.

Market cap history

$0 M$1.8 B$3.5 B$5.3 B$7.0 B2020202120222023202420252026

World rank over time

▲ up 23,621 places since 2020
2020-01-01: #26597#26,59720202021-01-01: #21661#21,66120212022-01-07: #28910#28,91020222022-12-25: #27057#27,05720222023-07-30: #27842#27,84220232024-01-05: #28107#28,10720242026-10-28: #2976#2,9762026

Rank in USA: #4,695 (Jan 2020) · #4,194 (Jan 2021) · #5,192 (Jan 2022) · #5,023 (Dec 2022) · #5,026 (Jul 2023) · #4,310 (Jan 2024) · #898 (Oct 2026)

Key ratios

market cap and latest results
P/E ratio
n/m (loss)
Price / sales
—
Price / book
13.8×
Free cash flow yield
-1.4%
Net margin
—
Operating margin
—
Return on equity
-22.3%
Liabilities / assets
3.4%
Profit per employee
$-1.6 M

Financial history

USD · fiscal years · source: SEC filings
RevenueNet income
Fiscal year ending Dec 2018: revenue —, net income $-8M—FY18Fiscal year ending Dec 2019: revenue —, net income $-5M—FY19Fiscal year ending Dec 2020: revenue —, net income $-10M—FY20Fiscal year ending Dec 2021: revenue —, net income $-19M—FY21Fiscal year ending Dec 2022: revenue —, net income $-10M—FY22Fiscal year ending Dec 2023: revenue —, net income $-5M—FY23Fiscal year ending Dec 2024: revenue —, net income $-84M—FY24Fiscal year ending Dec 2025: revenue —, net income $-105M—FY25
Fiscal year endingRevenueGrowthOperating incomeNet incomeNet margin
Dec 2025——$-122M$-105M—
Dec 2024——$-88M$-84M—
Dec 2023——$-7M$-5M—
Dec 2022——$-11M$-10M—
Dec 2021——$-19M$-19M—
Dec 2020——$-10M$-10M—
Dec 2019——$-6M$-5M—
Dec 2018——$-8M$-8M—

Cash flow, debt and per share

Fiscal year endingOperating cash flowCapital spendingFree cash flowEPS (diluted)Dividend / share
Dec 2025$-88M$0M$-88M——
Dec 2024$-58M$0M$-58M$-3.87—
Dec 2023$-5M$0M$-5M$-0.37—
Dec 2022$-11M$0M$-11M$-0.69—
Dec 2021$-19M$0M$-19M$-1.39—
Dec 2020$-8M$0M$-8M$-2.07—
Dec 2019$-5M$0M$-5M$-4.15—
Dec 2018$-8M$0M$-8M$-10.31—

Quarterly results

USD · three months to · source: SEC filings
RevenueNet income
Three months to Dec 2024 (from the annual report): revenue —, net income $-31M—Dec ’24Three months to Mar 2025: revenue —, net income $-21M—Mar ’25Three months to Jun 2025: revenue —, net income $-25M—Jun ’25Three months to Sep 2025: revenue —, net income $-30M—Sep ’25Three months to Dec 2025 (from the annual report): revenue —, net income $-30M—Dec ’25Three months to Mar 2026: revenue —, net income $-32M—Mar ’26Three months to Jun 2026: revenue —, net income $-41M—Jun ’26Three months to Sep 2026: revenue —, net income $-50M—Sep ’26

Latest quarter to Sep 2026: revenue —, net income $-50M. Lighter bars: fourth quarters worked out from the annual report. Trailing 12 months to Sep 2026.

SEC filings

Official filings of Oruka Therapeutics, Inc. with the US Securities and Exchange Commission.

Annual results

Revenue
—
Operating income
$-122 M
Net income
$-105 M

For year ending December-2025 · source: SEC filing

Balance sheet

Total assets
$489 M
Total liabilities
$17 M
Total equity
$472 M

As of December-2025

Top 100 institutional investors in Oruka Therapeutics, Inc.#

As of Sep 30, 2026
259 institutions held 76.7 M shares (more than all shares outstanding: lent and sub-advised shares are reported by more than one filer) on Sep 30, 2026. The ten largest hold 62.1%. Source: SEC Form 13F filings, filed through Nov 17, 2026. Change is since the previous quarter.This quarter is still being filed: about 99% of the institutions that reported last quarter have filed so far. Institutions that have not filed yet are missing from the list, not sellers; the list is brought up to date every day.
The 25 largest institutional investors in Oruka Therapeutics, Inc.
#InstitutionShares heldChange (shares)% heldValueFiled
1FMR LLC10,148,867+1,091,222 (+12.05%)14.96%$845 MNov 10, 2026
2BlackRock, Inc.5,210,214+220,033 (+4.41%)7.68%$434 MNov 13, 2026
3T. Rowe Price Investment Management, Inc.4,392,166+3,288,423 (+297.93%)6.48%$366 MNov 16, 2026
4Venrock Adviser, LLC4,148,4280 (0.00%)6.12%$346 MNov 16, 2026
5Fairmount Funds Management LLC3,705,2620 (0.00%)5.46%$309 MNov 16, 2026
6Capital World Investors3,429,066+27,427 (+0.81%)5.06%$286 MNov 12, 2026
7RTW Investments, LP3,139,0300 (0.00%)4.63%$261 MNov 16, 2026
8State Street Corp2,817,132+144,042 (+5.39%)4.15%$235 MNov 12, 2026
9Vanguard Capital Management LLC2,644,280+283,309 (+12.00%)3.90%$220 MNov 13, 2026
10Paradigm Biocapital Advisors LP2,493,507+348,981 (+16.27%)3.68%$208 MNov 16, 2026
11Franklin Templeton Inc2,033,669+412,218 (+25.42%)3.00%$169 MNov 12, 2026
12Janus Henderson Group Ltd.1,873,153—2.76%$156 MNov 16, 2026
13Bellevue Group AG1,641,059-16,131 (-0.97%)2.42%$137 MNov 16, 2026
14Vanguard Portfolio Management LLC1,592,427+1,010,018 (+173.42%)2.35%$133 MNov 13, 2026
15Ra Capital Management, L.P.1,554,5970 (0.00%)2.29%$129 MNov 16, 2026
16Geode Capital Management, LLC1,545,458+115,504 (+8.08%)2.28%$129 MNov 6, 2026
17Polar Capital Holdings Plc1,224,841-3,768 (-0.31%)1.81%$102 MNov 16, 2026
18Perceptive Advisors LLC1,072,363-272,700 (-20.27%)1.58%$89 MNov 16, 2026
19Deep Track Capital, LP1,069,774-856,226 (-44.46%)1.58%$89 MNov 16, 2026
20Price T Rowe Associates Inc /MD/966,767+128,164 (+15.28%)1.43%$81 MNov 16, 2026
21Remedium Capital Partners, LLC954,150-611,511 (-39.06%)1.41%$79 MNov 13, 2026
22Westfield Capital Management Co LP829,749+198,316 (+31.41%)1.22%$69 MNov 12, 2026
23Avidity Partners Management LP785,424+25,000 (+3.29%)1.16%$65 MNov 16, 2026
24Summit Partners Public Asset Management, LLC723,922+65,621 (+9.97%)1.07%$60 MNov 16, 2026
25Jpmorgan Chase & Co695,630+40,603 (+6.20%)1.03%$58 MNov 12, 2026
Show all 100: investors 26 to 100
Institutional investors 26 to 100 in Oruka Therapeutics, Inc.
#InstitutionShares heldChange (shares)% heldValueFiled
26Aberdeen Group plc632,408-14,535 (-2.25%)0.93%$53 MNov 10, 2026
27Affinity Asset Advisors, LLC600,000+10,000 (+1.69%)0.88%$50 MNov 13, 2026
28Goldman Sachs Group Inc582,289+402,850 (+224.51%)0.86%$48 MNov 16, 2026
29Charles Schwab Investment Management Inc520,681+87,276 (+20.14%)0.77%$43 MNov 16, 2026
30BNP Paribas Financial Markets459,528-619,487 (-57.41%)0.68%$38 MNov 12, 2026
31Northern Trust Corp446,386+17,495 (+4.08%)0.66%$37 MNov 16, 2026
32Voya Investment Management LLC412,814+11,665 (+2.91%)0.61%$34 MNov 10, 2026
33Vanguard Fiduciary Trust Co403,555+37,925 (+10.37%)0.59%$34 MNov 13, 2026
34Pictet Asset Management Holding SA401,928-217,148 (-35.08%)0.59%$33 MNov 3, 2026
35Cormorant Asset Management, LP400,000-133,340 (-25.00%)0.59%$33 MNov 16, 2026
36Adage Capital Partners GP, L.L.C.394,246+39,243 (+11.05%)0.58%$33 MNov 16, 2026
37Point72 Asset Management, L.P.373,455New0.55%$31 MNov 16, 2026
38Massachusetts Financial Services Co /ma/345,003-19,099 (-5.25%)0.51%$29 MNov 12, 2026
39Candriam S.C.A.339,032-13,684 (-3.88%)0.50%$28 MNov 3, 2026
40UBS Group AG320,044-319,319 (-49.94%)0.47%$27 MNov 10, 2026
41Braidwell LP319,679+41,515 (+14.92%)0.47%$27 MNov 16, 2026
42Lord, Abbett & Co. LLC306,236-83,828 (-21.49%)0.45%$26 MNov 13, 2026
43Jennison Associates LLC301,727+2,470 (+0.83%)0.44%$25 MNov 16, 2026
44MPM Bioimpact LLC300,000New0.44%$25 MNov 16, 2026
45Ghisallo Capital Management LLC300,000+250,000 (+500.00%)0.44%$25 MNov 16, 2026
46Eventide Asset Management, LLC295,000+55,000 (+22.92%)0.43%$25 MNov 13, 2026
47Holocene Advisors, LP291,573-14,378 (-4.70%)0.43%$24 MNov 16, 2026
48Woodline Partners LP285,952+705 (+0.25%)0.42%$24 MNov 16, 2026
49Bank Of America Corp /de/281,363-71,461 (-20.25%)0.41%$23 MNov 16, 2026
50Silverarc Capital Management, LLC247,918-104,884 (-29.73%)0.37%$21 MNov 12, 2026
51Nuveen, LLC241,116-8,151 (-3.27%)0.36%$20 MNov 10, 2026
52Nomura Asset Management International Inc.231,345+12,306 (+5.62%)0.34%$19 MNov 16, 2026
53Blackstone Inc.219,709-17,399 (-7.34%)0.32%$18 MNov 16, 2026
54Fisher Asset Management, LLC215,593+147,719 (+217.64%)0.32%$18 MNov 6, 2026
55Deutsche Bank AG\198,924+3,720 (+1.91%)0.29%$17 MNov 6, 2026
56SEB Asset Management AB196,7530 (0.00%)0.29%$16 MNov 4, 2026
57Barclays PLC170,500+95,738 (+128.06%)0.25%$14 MNov 6, 2026
58Handelsbanken Fonder AB165,077+4,177 (+2.60%)0.24%$14 MNov 9, 2026
59Millennium Management LLC158,558+125,692 (+382.44%)0.23%$13 MNov 16, 2026
60Bank of New York Mellon Corp143,461+2,591 (+1.84%)0.21%$12 MNov 5, 2026
61Victory Capital Management Inc130,940+6,662 (+5.36%)0.19%$11 MNov 10, 2026
62Dimensional Fund Advisors LP128,645+15,469 (+13.67%)0.19%$11 MNov 4, 2026
63TD Asset Management Inc128,562+25,618 (+24.89%)0.19%$11 MNov 13, 2026
64Synergy Asset Management, LLC127,852-228,449 (-64.12%)0.19%$11 MNov 5, 2026
65UBS AM, a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC124,390+20,080 (+19.25%)0.18%$10 MNov 16, 2026
66Morgan Stanley121,869+45,509 (+59.60%)0.18%$10 MNov 13, 2026
67Seven Grand Managers, LLC110,0000 (0.00%)0.16%$9 MNov 16, 2026
68Russell Investments Group, Ltd.104,433-8,510 (-7.53%)0.15%$9 MNov 6, 2026
69Squarepoint Ops LLC100,996New0.15%$8 MNov 9, 2026
70Invesco Ltd.97,255-27,403 (-21.98%)0.14%$8 MNov 12, 2026
71Apis Capital Advisors, LLC92,000-20,000 (-17.86%)0.14%$8 MNov 13, 2026
72Toronto Dominion Bank89,8370 (0.00%)0.13%$7 MNov 16, 2026
73Alps Advisors Inc87,745+26,731 (+43.81%)0.13%$7 MNov 3, 2026
74Schroder Investment Management Group81,088+59,635 (+277.98%)0.12%$7 MNov 16, 2026
75Neuberger Berman Group LLC79,473+77,263 (+3496.06%)0.12%$7 MNov 13, 2026
76Swiss National Bank77,400+14,400 (+22.86%)0.11%$6 MNov 12, 2026
77Prudential Financial Inc76,620-9,275 (-10.80%)0.11%$6 MNov 16, 2026
78Moody Aldrich Partners LLC74,806-26,605 (-26.23%)0.11%$6 MOct 27, 2026
79Ameriprise Financial Inc72,088-646 (-0.89%)0.11%$6 MNov 16, 2026
80Rafferty Asset Management, LLC69,824+26,714 (+61.97%)0.10%$6 MNov 13, 2026
81Alliancebernstein L.P.64,580-1,500 (-2.27%)0.10%$5 MNov 16, 2026
82Marshall Wace, LLP63,668New0.09%$5 MNov 13, 2026
83First Trust Advisors LP62,885+58,222 (+1248.60%)0.09%$5 MNov 12, 2026
84Secure Asset Management, LLC62,452-3,447 (-5.23%)0.09%$5 MOct 19, 2026
85Rhumbline Advisers62,380+1,596 (+2.63%)0.09%$5 MNov 10, 2026
86Manufacturers Life Insurance Company, The61,757-6,664 (-9.74%)0.09%$5 MNov 13, 2026
87Atom Investors LP61,227+45,706 (+294.48%)0.09%$5 MNov 16, 2026
88Federated Hermes, Inc.60,446+30,364 (+100.94%)0.09%$5 MNov 12, 2026
89Granahan Investment Management, LLC59,676+8,638 (+16.92%)0.09%$5 MNov 16, 2026
90Informed Momentum Co LLC59,649+635 (+1.08%)0.09%$5 MNov 16, 2026
91Principal Financial Group Inc58,837+19,061 (+47.92%)0.09%$5 MNov 2, 2026
92Ensign Peak Advisors, Inc58,707-8,961 (-13.24%)0.09%$5 MNov 12, 2026
93Viking Global Investors LP58,000-1,445,478 (-96.14%)0.09%$5 MNov 16, 2026
94Rhenman & Partners Asset Management AB55,900-24,100 (-30.12%)0.08%$5 MNov 12, 2026
95B Group, Inc.55,000-20,000 (-26.67%)0.08%$5 MNov 16, 2026
96Parkman Healthcare Partners LLC53,221-59,967 (-52.98%)0.08%$4 MNov 16, 2026
97Burkehill Global Management, LP50,0000 (0.00%)0.07%$4 MNov 16, 2026
98Kennedy Capital Management LLC47,140-59,723 (-55.89%)0.07%$4 MNov 13, 2026
99XTX Topco Ltd45,345+4,839 (+11.95%)0.07%$4 MNov 16, 2026
100California State Teachers Retirement System44,120+8,100 (+22.49%)0.07%$4 MNov 13, 2026

All 259 institutional investors, with who bought and sold →

Superinvestors holding Oruka Therapeutics, Inc.

2 of the well-known investors value.today follows, from their newest Form 13F.

Mutual funds holding Oruka Therapeutics, Inc.#

244 funds in 2 countries hold shares worth $2.1 B (about 36.5% of the company). Since their previous reports 197 added shares and 32 sold, buying $971 M net. By country: USA 238 ($2.1 B), Sweden 6 ($39 M).
Mutual funds holding Oruka Therapeutics, Inc.
FundSharesValueOf the companyOf the fundChange in sharesReport
🇺🇸 Vanguard Total Stock Market Index FundThe Vanguard Group, Inc.1.72 M$164 M2.5%<0.01%+25%Jun 30, 2026
🇺🇸 State Street SPDR S&P Biotech ETFSSGA Funds Management, Inc.1.56 M$148 M2.3%1.4%+104%Jun 30, 2026
🇺🇸 SMALLCAP World Fund IncSMALLCAP World Fund Inc1.53 M$145 M2.3%0.15%newJun 30, 2026
🇺🇸 iShares Russell 2000 ETFBlackRock Fund Advisors1.30 M$124 M1.9%0.15%+38%Jun 30, 2026
🇺🇸 Fidelity Growth Company FundFidelity Management & Research Company LLC1.22 M$71 M1.8%0.07%+200%May 31, 2026
🇺🇸 Fidelity Advisor Biotechnology FundFidelity Management & Research Company LLC737,386$71 M1.1%3.2%no changeJul 31, 2026
🇺🇸 Fidelity Small Cap Growth FundFidelity Management & Research Company LLC685,718$66 M1.0%0.75%no changeJul 31, 2026
🇺🇸 Vanguard Extended Market Index FundThe Vanguard Group, Inc.580,953$55 M0.86%0.06%+33%Jun 30, 2026
🇺🇸 Fidelity Small Cap Index FundFidelity Management & Research Company LLC550,743$53 M0.81%0.16%+44%Jul 31, 2026
🇺🇸 Select Health Care PortfolioFidelity Management & Research Company LLC833,100$49 M1.2%0.84%−17%May 31, 2026
🇺🇸 T. Rowe Price Health Sciences Fund, Inc.T. Rowe Price Associates, Inc.451,118$43 M0.67%0.36%−5.2%Jun 30, 2026
🇺🇸 iShares Russell 2000 Growth ETFBlackRock Fund Advisors449,195$43 M0.66%0.28%newJun 30, 2026
🇺🇸 Fidelity Advisor Health Care FundFidelity Management & Research Company LLC428,000$41 M0.63%1.3%+0.9%Jul 31, 2026
🇺🇸 T. Rowe Price Small-Cap Stock Fund, Inc.T. Rowe Price Associates, Inc.381,128$36 M0.56%0.39%newJun 30, 2026
🇺🇸 iShares Biotechnology ETFBlackRock Fund Advisors359,218$34 M0.53%0.38%+18%Jun 30, 2026
🇺🇸 Fidelity Stock Selector Small Cap FundFidelity Management & Research Company LLC344,956$33 M0.51%0.45%no changeJul 31, 2026
🇺🇸 Select Biotechnology PortfolioFidelity Management & Research Company LLC562,683$33 M0.83%0.63%+18%May 31, 2026
🇺🇸 Harbor Small Cap Growth FundHarbor Capital Advisors, Inc.316,518$31 M0.47%1.1%+186%Jul 31, 2026
🇺🇸 Fidelity Series Small Cap Opportunities FundFidelity Management & Research Company LLC301,472$29 M0.44%0.61%no changeJul 31, 2026
🇺🇸 Franklin Biotechnology Discovery FundFranklin Advisers, Inc.296,262$29 M0.44%2.5%−6.4%Jul 31, 2026
🇺🇸 Fidelity Small Cap Growth K6 FundFidelity Management & Research Company LLC295,854$29 M0.44%0.62%no changeJul 31, 2026
🇺🇸 abrdn Healthcare Investorsabrdn Inc.273,474$26 M0.40%1.9%newJun 30, 2026
🇺🇸 Putnam Small Cap Growth FundPutnam Investment Management, LLC255,628$24 M0.38%0.72%newJun 30, 2026
🇺🇸 JPMorgan Small Cap Growth FundJ.P. Morgan Investment Management Inc.250,999$24 M0.37%0.92%newJun 30, 2026
🇺🇸 abrdn Healthcare Opportunities Fundabrdn Inc.250,767$24 M0.37%2.9%newJun 30, 2026
🇺🇸 Eventide Healthcare & Life Sciences FundEventide Asset Management, LLC240,000$23 M0.35%1.3%newJun 30, 2026
🇺🇸 Lord Abbett Developing Growth Fund IncLord, Abbett & Co. LLC225,118$22 M0.33%0.98%+4.7%Jul 31, 2026
🇺🇸 Janus Henderson Global Life Sciences FundJanus Investment Fund222,082$21 M0.33%0.36%newJun 30, 2026
🇺🇸 Fidelity Growth Company K6 FundFidelity Management & Research Company LLC356,248$21 M0.53%0.08%+192%May 31, 2026
🇺🇸 Franklin Small Cap Growth FundFranklin Advisers, Inc.208,013$20 M0.31%0.81%−2.4%Jul 31, 2026
🇺🇸 T. Rowe Price Institutional Small-Cap Stock FundT. Rowe Price Associates, Inc.205,065$20 M0.30%0.39%newJun 30, 2026
🇺🇸 Fidelity Series Growth Company FundFidelity Management & Research Company LLC323,236$19 M0.48%0.08%+203%May 31, 2026
🇸🇪 SEB LäkemedelsfondSEB Funds AB196,753$19 M0.29%1.0%newJun 30, 2026
🇺🇸 Nomura Healthcare FundDelaware Management Company190,000$18 M0.28%2.4%newJun 30, 2026
🇺🇸 Fidelity ContrafundFidelity Management & Research Company LLC185,075$18 M0.27%<0.01%newJun 30, 2026
🇺🇸 New Economy FundCapital Research and Management Company285,714$17 M0.42%0.03%newMay 31, 2026
🇺🇸 BlackRock Health Sciences Opportunities PortfolioBlackRock Advisors, LLC264,813$15 M0.39%0.26%+43%May 29, 2026
🇺🇸 Fidelity Extended Market Index FundFidelity Management & Research Company LLC252,250$15 M0.37%0.03%+24%May 31, 2026
🇺🇸 T. Rowe Price Integrated U.S. Small-Cap Growth Equity FundT. Rowe Price Associates, Inc.150,800$14 M0.22%0.15%newJun 30, 2026
🇺🇸 VIP Health Care PortfolioFidelity Management & Research Company LLC149,300$14 M0.22%1.2%−7.9%Jun 30, 2026
🇺🇸 Vanguard Russell 2000 Index FundThe Vanguard Group, Inc.237,730$14 M0.35%0.08%+24%May 31, 2026
🇺🇸 Schwab U.S. Small-Cap ETFCharles Schwab Investment Management, Inc.234,870$14 M0.35%0.06%+22%May 31, 2026
🇺🇸 Fidelity Blue Chip Growth FundFidelity Management & Research Company LLC129,200$12 M0.19%0.01%no changeJul 31, 2026
🇺🇸 Schwab Small-Cap Index FundCharles Schwab Investment Management, Inc.122,470$12 M0.18%0.16%+45%Jul 31, 2026
🇺🇸 abrdn Life Sciences Investorsabrdn Inc.122,702$12 M0.18%1.7%+62%Jun 30, 2026
🇺🇸 Fidelity SAI Small-Mid Cap Momentum Index FundFidelity Management & Research Company LLC119,794$12 M0.18%0.28%newJul 31, 2026
🇸🇪 Handelsbanken Hälsovård TemaHandelsbanken Fonder AB107,000$10 M0.16%0.40%newJun 30, 2026
🇺🇸 College Retirement Equities Fund - Total Global Stock AccountTIAA-CREF Investment Management, LLC96,464$9 M0.14%<0.01%newJun 30, 2026
🇺🇸 Master Small Cap Index SeriesBlackRock Advisors, LLC92,609$9 M0.14%0.15%+49%Jun 30, 2026
🇺🇸 Janus Henderson Small/Mid Cap Growth Alpha ETFJanus Henderson Investors US LLC82,097$8 M0.12%0.75%newJul 31, 2026
🇺🇸 JPMorgan Small Cap Blend FundJ.P. Morgan Investment Management Inc.80,748$8 M0.12%0.45%newJun 30, 2026
🇺🇸 Vanguard Explorer FundThe Vanguard Group, Inc.78,586$8 M0.12%0.03%newJul 31, 2026
🇺🇸 Fidelity U.S. Equity Central FundFidelity Management & Research Company LLC75,600$7 M0.11%0.03%newJun 30, 2026
🇺🇸 MFS New Discovery Value FundMASSACHUSETTS FINANCIAL SERVICES COMPANY122,006$7 M0.18%0.29%newMay 31, 2026
🇺🇸 MFS New Discovery FundMASSACHUSETTS FINANCIAL SERVICES COMPANY121,469$7 M0.18%0.33%newMay 31, 2026
🇺🇸 Bridge Builder Small/Mid Cap Value FundOLIVE STREET INVESTMENT ADVISERS LLC74,423$7 M0.11%0.07%+333%Jun 30, 2026
🇺🇸 iShares Core S&P Total U.S. Stock Market ETFBlackRock Fund Advisors67,743$6 M0.10%<0.01%+20%Jun 30, 2026
🇺🇸 Invesco Dorsey Wright Healthcare Momentum ETFInvesco Capital Management LLC66,716$6 M0.10%2.7%+136%Jul 31, 2026
🇺🇸 Strategic Advisers Fidelity U.S. Total Stock FundStrategic Advisers LLC108,900$6 M0.16%<0.01%newMay 31, 2026
🇺🇸 Nuveen Small Cap Blend Index FundTeachers Advisors, LLC65,695$6 M0.10%0.16%+46%Jul 31, 2026
🇺🇸 BlackRock Health Sciences Term TrustBlackRock Advisors, LLC65,030$6 M0.10%0.57%+34%Jun 30, 2026
🇺🇸 Vanguard Health Care Index FundThe Vanguard Group, Inc.94,188$6 M0.14%0.03%+44%May 31, 2026
🇺🇸 Fidelity Total Market Index FundFidelity Management & Research Company LLC92,125$5 M0.14%<0.01%+22%May 31, 2026
🇺🇸 EQ/2000 Managed Volatility PortfolioEquitable Investment Management Group, LLC54,205$5 M0.08%0.14%+36%Jun 30, 2026
🇺🇸 Direxion Daily S&P Biotech Bull 3X SharesRAFFERTY ASSET MANAGEMENT, LLC52,700$5 M0.08%1.0%+21%Jul 31, 2026
🇺🇸 Avantis U.S. Small Cap Equity ETFAmerican Century ETF Trust81,774$5 M0.12%0.17%+39%May 31, 2026
🇺🇸 Victory RS Small Cap Growth FundVictory Capital Management Inc.48,680$5 M0.07%1.1%newJun 30, 2026
🇺🇸 Fidelity Small Cap Growth Index FundFidelity Management & Research Company LLC47,198$4 M0.07%0.29%newJun 30, 2026
🇺🇸 VIP Contrafund PortfolioFidelity Management & Research Company LLC47,000$4 M0.07%0.01%newJun 30, 2026
🇺🇸 PGIM Jennison Health Sciences FundPGIM INVESTMENTS LLC76,396$4 M0.11%0.32%newMay 29, 2026
🇺🇸 Fidelity Series Total Market Index FundFidelity Management & Research Company LLC75,066$4 M0.11%<0.01%+21%May 31, 2026
🇺🇸 VictoryShares US Small Mid Cap Value Momentum ETFVictory Capital Management Inc.45,839$4 M0.07%0.25%newJun 30, 2026
🇺🇸 MFS New Discovery SeriesMASSACHUSETTS FINANCIAL SERVICES COMPANY44,125$4 M0.07%0.51%newJun 30, 2026
🇺🇸 Fidelity Enhanced Small Cap Core ETFFidelity Management & Research Company LLC42,994$4 M0.06%0.07%newJun 30, 2026
🇺🇸 Dimensional U.S. Small Cap ETFDimensional Fund Advisors LP42,314$4 M0.06%0.03%no changeJul 31, 2026
🇺🇸 SMALLCAP World FundCapital Research and Management Company42,375$4 M0.06%0.16%newJun 30, 2026
🇺🇸 Fidelity Advisor New Insights FundFidelity Management & Research Company LLC41,700$4 M0.06%0.01%newJun 30, 2026
🇺🇸 Fidelity Balanced FundFidelity Management & Research Company LLC67,700$4 M0.10%<0.01%newMay 31, 2026
🇺🇸 Multi-Manager Directional Alternative Strategies FundColumbia Management Investment Advisers, LLC40,805$4 M0.06%1.2%+59%Jul 31, 2026
🇸🇪 Handelsbanken Amerika Småbolag TemaHandelsbanken Fonder AB40,000$4 M0.06%0.41%newJun 30, 2026
🇺🇸 Nuveen Equity Index FundTeachers Advisors, LLC38,921$4 M0.06%<0.01%+11%Jul 31, 2026
🇺🇸 Fidelity Contrafund K6Fidelity Management & Research Company LLC38,715$4 M0.06%<0.01%newJun 30, 2026
🇺🇸 LVIP State Street Small-Cap Index FundLincoln Financial Investments Corporation35,495$3 M0.05%0.15%+42%Jun 30, 2026
🇸🇪 HealthInvest Sustainable HealthcareAtle Fund Management AB35,313$3 M0.05%0.90%newJun 30, 2026
🇺🇸 Federated Hermes MDT Small Cap Growth FundFederated Hermes MDT Series33,226$3 M0.05%0.38%newJul 31, 2026
🇺🇸 Schwab Total Stock Market Index FundCharles Schwab Investment Management, Inc.32,257$3 M0.05%<0.01%+34%Jul 31, 2026
🇺🇸 Victory Small Cap Stock FundVictory Capital Management Inc.32,066$3 M0.05%0.32%newJul 31, 2026
🇺🇸 Capital Group U.S. Small and Mid Cap ETFCapital Research and Management Company52,068$3 M0.08%0.11%newMay 31, 2026
🇺🇸 ALPS Medical Breakthroughs ETFALPS Advisors, Inc.49,896$3 M0.07%1.8%+16%May 31, 2026
🇺🇸 EQ/Small Company Index PortfolioEquitable Investment Management Group, LLC29,860$3 M0.04%0.15%+42%Jun 30, 2026
🇺🇸 Vanguard Balanced Index FundThe Vanguard Group, Inc.29,232$3 M0.04%<0.01%+17%Jun 30, 2026
🇺🇸 Optimum Small-Mid Cap Growth FundDelaware Management Company29,039$3 M0.04%0.29%newJun 30, 2026
🇺🇸 U.S. Micro Cap PortfolioDimensional Fund Advisors LP28,599$3 M0.04%0.04%no changeJul 31, 2026
🇺🇸 Janus Henderson Small Cap Growth Alpha ETFJanus Henderson Investors US LLC28,596$3 M0.04%0.76%newJul 31, 2026
🇺🇸 T. Rowe Price Health Sciences PortfolioT. Rowe Price Associates, Inc.28,926$3 M0.04%0.37%no changeJun 30, 2026
🇺🇸 Nuveen Small Cap Select FundNuveen Fund Advisors, LLC27,900$3 M0.04%0.66%newJul 31, 2026
🇺🇸 Fidelity ZERO Total Market Index FundFidelity Management & Research Company LLC27,467$3 M0.04%<0.01%+36%Jul 31, 2026
🇺🇸 Fidelity Fundamental Small-Mid Cap ETFFidelity Management & Research Company LLC26,725$3 M0.04%0.17%newJul 31, 2026
🇺🇸 Vanguard U.S. Momentum Factor ETFThe Vanguard Group, Inc.43,678$3 M0.06%0.14%−31%May 31, 2026
🇺🇸 Fidelity Blue Chip Growth K6 FundFidelity Management & Research Company LLC26,386$3 M0.04%0.01%−0.8%Jul 31, 2026

Source: Fund portfolio reports to the SEC (Form N-PORT), CVM, Finansinspektionen and Indian fund houses · as of Jul 31, 2026. The 100 largest positions, each from the fund's newest report; report dates differ between funds. A fund family's funds are listed one by one, so one manager can appear many times.

Insider trading at Oruka Therapeutics, Inc.#

Shares bought and sold by directors, officers and 10% owners, from their SEC Form 4 filings.

Bought, 12 months
$0
0 purchases, 0 insiders
Sold, 12 months
$343.7 M
145 sales, 8 insiders
Net, 12 months
-$343.7 M
open market only
Insiders on file
39
since
$2.1 M-$301.9 M$0Jul 2024: bought $2.1 M (13 trades), sold $0 (0 trades)Jul 24Aug 2024: bought $17 K (2 trades), sold $0 (0 trades)Feb 2025: bought $1.4 M (5 trades), sold $0 (0 trades)FebDec 2025: bought $0 (0 trades), sold $214 K (4 trades)Jan 2026: bought $0 (0 trades), sold $594 K (5 trades)Jan 26Feb 2026: bought $0 (0 trades), sold $227 K (2 trades)Mar 2026: bought $0 (0 trades), sold $623 K (10 trades)MarApr 2026: bought $0 (0 trades), sold $463 K (3 trades)May 2026: bought $0 (0 trades), sold $7.6 M (16 trades)MayJun 2026: bought $0 (0 trades), sold $4.0 M (15 trades)Jul 2026: bought $0 (0 trades), sold $301.9 M (12 trades)JulAug 2026: bought $0 (0 trades), sold $7.5 M (15 trades)Sep 2026: bought $0 (0 trades), sold $10.4 M (23 trades)SepOct 2026: bought $0 (0 trades), sold $4.1 M (17 trades)Nov 2026: bought $0 (0 trades), sold $6.0 M (23 trades)Nov
Bought (open market)Sold (open market)Hover a month for the totals
Oruka Therapeutics, Inc.: latest insider trades
TradedInsiderTradeSharesPriceValueOwned afterFiling
filed Joana GoncalvesChief Medical OfficerOption exercise10b5-1 plan+3,500$6.840$24 K35,271Form 4
filed Joana GoncalvesChief Medical OfficerOption exercise10b5-1 plan+3,500$7.800$27 K38,771Form 4
filed Joana GoncalvesChief Medical OfficerSell10b5-1 plan-2,600$99.52$259 K36,171Form 4
filed Joana GoncalvesChief Medical OfficerSell10b5-1 plan-1,500$100.48$151 K34,671Form 4
filed Joana GoncalvesChief Medical OfficerSell10b5-1 plan-1,900$101.53$193 K32,771Form 4
filed Joana GoncalvesChief Medical OfficerSell10b5-1 plan-300$102.47$31 K32,471Form 4
filed Joana GoncalvesChief Medical OfficerSell10b5-1 plan-200$103.36$21 K32,271Form 4
filed Joana GoncalvesChief Medical OfficerSell10b5-1 plan-500$105.86$53 K31,771Form 4

Source: SEC Forms 4 and 5. Awards, option exercises and shares withheld for tax are listed but not counted in the totals

Markets and events: Oruka Therapeutics, Inc.#

Short interest, dividends, buybacks, splits, index changes and other events from FINRA, the SEC and the exchanges.

Short interest, 2026-10-30
6.5 M
13.3% of shares · 7.06 days to cover
Shares sold short, last 24 reportsAll stocks →

Stock splits: 1-for-6.99 reverse split in the period to ; 1-for-5.99 reverse split in the period to

Fails to deliver

  • : 4 shares at $95.81
  • : 3,310 shares at $81.15
  • : 15,722 shares at $79.92
  • : 340 shares at $79.09
  • : 62,016 shares at $83.29

Source: FINRA, SEC EDGAR (8-K, S-1/F-1, 424B4, XBRL, fails-to-deliver), Nasdaq Trader, Wikipedia index change tables

Oruka Therapeutics, Inc. scorecard#

Passes 1 of the 10 checks that could be worked out. Fiscal year 2025; market cap of Oct 28, 2026.

  • Valuation0 of 4
    • ✗P/E below its peers' medianNo P/EThe company made a loss over the last twelve months.
    • ✗Price to book below its peers' median13.8×Price to book 13.8× against Biotechnology's median of 2.9×.
    • –Price to sales below its peers' medianNo Price to sales on file.
    • ✗Free cash flow yield above 5%-1.4%Free cash flow is -1.4% of the market value.
    • ✗Earnings yield above the 10-year Treasury yieldLossA loss earns nothing against the 10-year Treasury's 5.15% (2026-11-13).
    • –The price assumes slower growth than the last three years'Free cash flow of the last three years is missing or below zero on average.
  • Growth0 of 1
    • –Revenue grew in the newest yearRevenue of the year before is not on file.
    • –Revenue up more than 5% a year over three yearsRevenue of three years earlier is not on file.
    • –Faster growth over three years than its peers' medianRevenue of three years earlier is not on file.
    • –Earnings per share grew in the newest yearEarnings per share of two years are not on file.
    • ✗Net income higher than five years earlier-$105 M-$105 M in fiscal 2025 against -$10 M in 2020.
    • –Revenue rose in at least four of the last five yearsFive years of revenue changes are not on file.
  • Profitability0 of 3
    • ✗Profitable in the newest year-$105 MNet income -$105 M in fiscal 2025.
    • ✗Profitable in each of the last five years0 of 5Profitable in 0 of the five years to fiscal 2025.
    • –Operating margin above its peers' medianNo operating margin on file.
    • ✗Return on equity above 15%-24.7%-24.7% in fiscal 2025.
    • –Return on invested capital above 10%No return on invested capital on file.
    • –Operating margin wider than three years earlierOperating margins of three years earlier are not on file.
  • Financial health1 of 2
    • ✓Short-term assets cover short-term liabilities22.4×Current ratio 22.37 at the end of fiscal 2025.
    • –Debt below equityDebt or equity is not on file (or equity is negative).
    • –Net debt below three years of EBITDANet debt to EBITDA is not on file.
    • –Operating income covers interest five timesInterest expense is not on file.
    • ✗Cash from operations positive in each of the last three years0 of 3Positive in 0 of the three years to fiscal 2025.
    • –Altman Z-score outside the distress zoneThe Z-score's figures are not all on file.
  • Shareholder returnsnot known
    • –Pays a dividendDividends are not on file.
    • –Dividend per share raised five years in a rowSix years of dividends per share are not on file.
    • –Dividends under 75% of net incomePays no dividend (or dividends are not on file).
    • –Share count up no more than 2% in a yearShare counts of two years are not on file.
    • –Dividends and buybacks above 3% of the market valueDividends and buybacks are not on file.
    • –Free cash flow covers dividends and buybacksPaid out nothing in the newest year.

Worked out from the statements as filed (sec), the medians of Biotechnology, the 10-year Treasury yield of Nov 13, 2026 and the market cap. A check that cannot be worked out counts neither way. A reading aid, not advice. How the checks work

Oruka Therapeutics, Inc.: financial statements#

Income statement, balance sheet and cash-flow statement as reported, newest period first.

Amounts in USD millions; per-share figures in USD; share counts in millions. Hover a figure for its filing and XBRL tag. Growth compares with the year before; shares are of revenue (income and cash flow) or of total assets (balance sheet).

Oruka Therapeutics, Inc.: statements by fiscal year
PeriodTrendFY 2025to Dec 31, 2025FY 2023to Dec 31, 2023FY 2022to Dec 31, 2022FY 2021to Dec 31, 2021FY 2020to Dec 31, 2020FY 2019to Dec 31, 2019FY 2018to Dec 31, 2018FY 2017to Dec 31, 2017FY 2016to Dec 31, 2016FY 2015to Dec 31, 2015
Income statement
Revenue—000000000
Research and development1011.04.7145.01.84.214127.1
General and administrative216.35.85.54.84.03.94.64.34.4
Operating expenses1227.311199.85.88.1191711
Operating income−122−7.3−11−19−9.8−5.8−8.1−19−17−11
Interest and finance income17—————————
Interest expense and finance costs————0.00.00.00.0—0.0
Other non-operating income (expense)17—————————
Income before tax−105——−19−9.7−5.6−8.0−19−16—
Income tax—000−0.0−0.2−0.0−0.100
Net income attributable to shareholders−105−5.3−9.9−19−9.7−5.5−7.9−18−16−11
Earnings per share, basic—-0.37-0.69-1.39-2.07-4.15-10.31r-1.77-1.81-1.82
Earnings per share, diluted—-0.37-0.69-1.39-2.07-4.15-10.31r-1.77-1.81-1.82
Shares, weighted average (basic)—141414——————
Shares, weighted average (diluted)—1414144.71.30.8r109.16.3
Balance sheet
Cash and cash equivalents47374253498.46.68.77.439
Short-term investments290——————3.114—
Other current assets6.80.20.31.10.90.10.20.50.30.1
Current assets344384354508.56.8122139
Property, plant and equipment0.30.00.00.00.00.00.00.00.10.0
Right-of-use (leased) assets1.80.20.30.40.40.0————
Total assets489384355508.56.8122540
Accounts payable4.20.40.31.11.80.40.20.61.20.4
Current liabilities150.61.13.53.50.90.82.12.41.5
Lease liabilities (non-current)1.30.20.30.40.4—————
Total liabilities170.81.43.93.90.90.82.12.41.5
Retained earnings−189−189−183−173−154−144−139−131−113−96
Shareholders' equity472374251477.66.0102238
Total liabilities and equity489384355508.56.8122540
Shares outstanding491514149.51.60.8r129.19.1
Cash-flow statement
Depreciation and amortization—0.00.00.00.00.00.00.00.00.0
Share-based compensation240.70.60.50.00.20.30.50.60.6
Cash from operating activities−88−5.0−11−19−7.7−4.8−8.2−17−15−11
Capital expenditure−0.20−0.0−0.0−0.0−0.0−0.0−0.0−0.0−0.0
Cash from investing activities−970−0.0−0.0−0.0−0.03.013−16−0.0
Shares issued0.7——24517.33.56.6—37
Cash from financing activities1700023486.63.15.8—34
Change in cash—−5.0−114.3411.8−2.11.3——
Report10-Q10-K10-K10-K10-K10-K10-K10-K10-K10-K

r Changed after it was first reported (a restatement, a reclassification or a later report's rounding); hover for the first value and filing, or show every figure as first reported: what investors could read at the time, without look-ahead. Restatements across companies

Build a DCF model from these statements: revenue, margins, tax, depreciation, capital spending, working capital, debt, cash and shares filled in from the annual reports, every assumption yours.

Source: SEC EDGAR filings (XBRL) · as of Sep 30, 2026. A fiscal year is listed under the calendar year it mostly falls in; quarters are numbered within the company's fiscal year. Balance-sheet figures are those at the end of each period. Payments in the cash-flow statement are negative

Where Oruka Therapeutics, Inc. operates: 1 country#

Countries where the company has its headquarters, an office, subsidiaries, a branch or reported revenue. 1 subsidiaries on file.

Present: offices, subsidiaries, branches or revenue (1 country)Nothing on fileDots mark countries too small to see. Hover, tap or tab to a country for its figures.

Only the headquarters country is on file for Oruka Therapeutics, Inc.: no subsidiaries, branches, offices or country revenue elsewhere in the GLEIF register, its SEC filings or Wikidata.

Oruka Therapeutics, Inc.: countries of operation
CountryPresenceRevenue there
🇺🇸 USAHeadquarters1 office1 subsidiary—

Source: GLEIF legal-entity register, SEC Exhibit 21 and annual reports, office addresses on file; map outlines from Natural Earth. A country without subsidiaries or offices on record is not listed even if the company sells there. How presence is decided

Executive pay at Oruka Therapeutics, Inc.#

From the pay-versus-performance table of the company's proxy statement. “Actually paid” marks share awards to their current value.

CEO total pay, fiscal 2025
$3.4 M
Other top executives, average
$2.3 M
the CEO earned 1.4× this
$100 invested is now
$107
Oruka Therapeutics, Inc.: executive pay by fiscal year
Fiscal yearCEO total payActually paidOther executives, average$100 invested
2025Chief executive$3.4 M$16.0 M$2.3 M$107
2024Chief executive$854 K$848 K$462 K$100
2023Chief executive$359 K$291 K$362 K$72

Source: SEC proxy statement (Form DEF 14A) · as of Dec 31, 2025

Events at Oruka Therapeutics, Inc.#

What the company reported to the SEC within four business days (Form 8-K), newest first.

Warning signs in the last three years

  • Auditor changedFiling

Auditor changed 1 · Change in control 1 · Acquisition or sale completed 1 · Directors and officers 5 · Material agreement 7 · Unregistered share sale 2 · Shareholder rights changed 1 · Bylaws or fiscal year changed 2 · Shareholder vote 4 · Results announced 5

Oruka Therapeutics, Inc.: events reported to the SEC
FiledWhat happenedFiling
Directors and officers8-K
Results announced8-K
Shareholder vote8-K
Results announced8-K
Directors and officers8-K
Material agreementUnregistered share sale8-K
Directors and officers8-K
Shareholder vote8-K
Material agreement8-K
Material agreement8-K
Shareholder vote8-K
Directors and officers8-K
Material agreementUnregistered share saleBylaws or fiscal year changed8-K
Auditor changedChange in controlAcquisition or sale completedDirectors and officersMaterial agreementShareholder rights changedBylaws or fiscal year changedResults announced8-K
Shareholder vote8-K
Material agreement8-K
Results announced8-K
Material agreement8-K
Results announced8-K

Source: SEC EDGAR, Form 8-K item numbers · as of Aug 24, 2026

Acquisitions and funding#

1 private funding rounds before listing

Private share sales · funding history

Private share sales of Oruka Therapeutics, Inc.
MonthRaisedRaiseSizeInvestorsSoldFiling
Jun 2015$52 MPrivate placement after listing$50 to $250 million14equity, optionsSEC
Jun 2013$1 MPrivate placement after listingUnder $2 million2optionsSEC
Jan 2013$1 MPrivate placement after listingUnder $2 million5equity, optionsSEC
Dec 2011$5 MNo. 1$2 to $10 million6equity, optionsSEC

Source: Annual reports and Form D notices filed with the SEC; Wikidata. Acquisitions are the businesses the company reports as acquired in its newest annual report, with the price paid. Funding rounds do not name their investors; the investors listed are those Wikidata records.

Layoffs at Oruka Therapeutics, Inc.#

From US state WARN notices and SEC 8-K restructuring filings, newest first.

People, last 12 months
0
0 notices and filings
People, all years
40
2007–2009
Latest
—
2009-09-18
Oruka Therapeutics, Inc.: people laid off by year and month
YearJanFebMarAprMayJunJulAugSepOctNovDecTotal
2009····40·······40
2008············—
2007············—
Oruka Therapeutics, Inc.: latest layoffs
AnnouncedPeopleKindWhereSource
Not statedRestructuring planSEC 8-KCompany-wide planFiling
40 peopleRestructuring planSEC 8-K“(the “Company”) implemented a plan of restructuring under which it will terminate approximately 40 employees, effective May 20, 2009.”Filing
37% of workforceRestructuring planSEC 8-K“(the “Company” or “Nuvelo”) adopted a plan of restructuring involving the termination of 20 research employees to reduce its current workforce by 37% percent.”Filing
22% of workforceRestructuring planSEC 8-K“On March 17, 2008, Nuvelo announced that in connection with the discontinuation of its alfimeprase clinical development program, described below under Items 7.01 and 8.01, it was t…”Filing
30% of workforceRestructuring planSEC 8-K“On August 1, 2007, Nuvelo announced that it was terminating employees to reduce its current workforce by approximately 30 percent and will suspend development of its product candid…”Filing

Source: State WARN notices and SEC 8-K item 2.05

Discuss Oruka Therapeutics, Inc.#

2 automatic updates and 0 member comments. Sign in to comment and react.

  • Insider trading in October 2026automatic update · Oct 31, 2026

    Directors and officers of Oruka Therapeutics, Inc. reported open-market trades for October 2026 (SEC Forms 4 and 5): 4 insiders sold shares worth about $4,126,865 in 17 trades. Awards, option exercises and shares withheld for tax are not counted.

  • Mutual funds: 244 funds hold $2.1 billionautomatic update · Jul 31, 2026

    244 mutual funds in 2 countries hold shares of Oruka Therapeutics, Inc. worth $2.1 billion, about 36.5% of the company (funds' newest reports, up to 31 July 2026). Since their previous reports 197 funds added shares and 32 sold; on balance they bought $971 million. Share splits are not counted as trading.

How Oruka Therapeutics, Inc. compares in Biotechnology

  • Market cap$6.5 B · higher than 92% of 726
  • Price / book13.8× · lower than 11% of 534
  • FCF yield-1.4% · higher than 84% of 449

Peer comparison · Biotechnology

CompanyMarket capP/ENet marginRev. growth
Oruka Therapeutics, Inc.🇺🇸$6.5 B———
Novo Nordisk A/S🇩🇰$203.2 B13.1×33.1%+10.8%
Vertex Pharmaceuticals Incorporated🇺🇸$134.3 B33.8×30.7%+8.9%
Moderna, Inc.🇺🇸$90.1 B—-110.5%-39.9%
Regeneron Pharmaceuticals, Inc.🇺🇸$84.1 B17.5×28.5%+1.0%
Argenx SE🇳🇱$52.8 B40.9×31.1%+89.9%
CSL Limited🇦🇺$51.6 B—-16.4%—
Samsung Biologics Co., Ltd.🇰🇷$51.5 B40.5×39.2%—
UCB SA🇧🇪$48.6 B26.3×20.1%+31.1%

P/E and margins use trailing 12-month results where available; growth is the latest fiscal year.

Questions, comparisons and similar companies#

Sources and freshness

Market cap:
Oct 28, 2026
Annual results:
For year ending December-2025
Balance sheet:
As of December-2025
Employees:
As of December 31, 2025
Profile updated:
Nov 20, 2026

Figures from Market data, SEC filing, value.today research, GLEIF register; financial statements from SEC filings.

How each figure is collected: data sources and methodology. Market caps in US dollars unless you switch the currency.

Work at Oruka Therapeutics, Inc.? Verify and update this profile — free

Use your work e-mail address (on the company's own domain if possible). Fill in only what is new or missing; a link to where the figures are published (annual report, press release) speeds up the review.

Show Oruka Therapeutics, Inc.'s ranking or a chart on your website Get the badge
Badge preview

The badge updates itself as the ranking changes.

Something wrong or missing about Oruka Therapeutics, Inc.? Suggest a correction